Tango Therapeutics(TNGX) - 2023 Q4 - Annual Results

– First patient dosed in phase 1/2 clinical trial of TNG348 in patients with BRCA1/2-mutant and other HRD+ cancers – – FDA Orphan Drug Designation granted for TNG462 for the treatment of soft tissue sarcomas – – Strong cash position of $337 million as of December 31, 2023, combined with $42 million in proceeds from ATM in January 2024; cash runway into late 2026 expected to fund all clinical programs through proof-of-concept – BOSTON, Mass. – March 18, 2024 – Tango Therapeutics, Inc. (NASDAQ: TNGX), a clini ...